| __timestamp | Merus N.V. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3852327 | 49315000 |
| Thursday, January 1, 2015 | 839656 | 75043000 |
| Friday, January 1, 2016 | 4478145 | 83749000 |
| Sunday, January 1, 2017 | 16432324 | 122682000 |
| Monday, January 1, 2018 | 11890871 | 207761000 |
| Tuesday, January 1, 2019 | 34110000 | 284812000 |
| Wednesday, January 1, 2020 | 35781000 | 317875000 |
| Friday, January 1, 2021 | 40896000 | 282660000 |
| Saturday, January 1, 2022 | 52200000 | 451421000 |
| Sunday, January 1, 2023 | 59836000 | 481871000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, effective cost management is crucial. This analysis of SG&A (Selling, General, and Administrative) expenses from 2014 to 2023 for Sarepta Therapeutics, Inc. and Merus N.V. offers a fascinating glimpse into their financial strategies. Over this period, Sarepta Therapeutics has seen a staggering 878% increase in SG&A expenses, reflecting its aggressive growth and expansion strategies. In contrast, Merus N.V. has experienced a more modest 1,454% rise, indicating a steady scaling of operations. Notably, in 2023, Sarepta's SG&A expenses were approximately eight times higher than Merus's, highlighting the differing scales and operational focuses of these companies. This data underscores the importance of strategic financial planning in the biotech sector, where balancing innovation with cost efficiency can be the key to long-term success.
Pfizer Inc. or Merus N.V.: Who Manages SG&A Costs Better?
United Therapeutics Corporation vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs ADMA Biologics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and CRISPR Therapeutics AG
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Soleno Therapeutics, Inc.
Opthea Limited and Merus N.V.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Ultragenyx Pharmaceutical Inc. vs Merus N.V.
Bausch Health Companies Inc. vs Merus N.V.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Merus N.V. and Protagonist Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Merus N.V. and Supernus Pharmaceuticals, Inc.
Merus N.V. vs Novavax, Inc.: SG&A Expense Trends